Quanterix (QTRX) Q2 FY26 earnings call

Quanterix reported Q2 FY26 results below expectations, driven by broad market softness and commercial execution issues, leading to a significant reduction in full-year revenue and margin guidance. The company is implementing a major commercial reorganization, including new leadership and a solution-based sales model, while prudently investing in its differentiated Alzheimer's diagnostics business. Despite the challenges, cash preservation was better than planned, and the company remains confident in its long-term strategy for both research tools and diagnostics.